Cytori Therapeutics, Inc. (NASDAQ:CYTX)(Frankfurt:XMPA) today announced financial results for the quarter ended June 30, 2006 and outlined plans for its upcoming clinical trials of adipose-derived stem and regenerative cells (ADRC) for cardiovascular indications in Europe.
